WGS GeneDx Holdings Corp
Price (delayed)
$37.72
Market cap
$1.02B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.44
Enterprise value
$1.08B
Sema4 is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic
Highlights
GeneDx Holdings's EPS has surged by 89% YoY and by 14% QoQ
The net income has soared by 76% YoY and by 13% QoQ
WGS's debt has surged by 55% year-on-year
The company's equity fell by 34% YoY and by 6% QoQ
Key stats
What are the main financial stats of WGS
Market
Valuations
Earnings
Shares outstanding
26.94M
Market cap
$1.02B
Enterprise value
$1.08B
Price to earnings (P/E)
N/A
Price to book (P/B)
5.08
Price to sales (P/S)
4.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.42
Revenue
$243.66M
EBIT
-$116.91M
EBITDA
-$91.83M
Free cash flow
-$95.89M
Per share
Balance sheet
Liquidity
EPS
-$4.44
Free cash flow per share
-$3.6
Book value per share
$7.42
Revenue per share
$9.15
TBVPS
$8.4
Total assets
$389.1M
Total liabilities
$195.06M
Debt
$116.96M
Equity
$194.04M
Working capital
$93.9M
Debt to equity
0.6
Current ratio
2.38
Quick ratio
1.95
Net debt/EBITDA
-0.66
Margins
Efficiency
Dividend
EBITDA margin
-37.7%
Gross margin
56%
Net margin
-48.2%
Operating margin
-38.1%
Return on assets
-29%
Return on equity
-53.2%
Return on invested capital
-59.1%
Return on capital employed
-36.4%
Return on sales
-48%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
WGS stock price
How has the GeneDx Holdings stock price performed over time
Intraday
-0.4%
1 week
11.83%
1 month
9.11%
1 year
761.19%
YTD
1,271.64%
QTD
44.3%
Financial performance
How have GeneDx Holdings's revenue and profit performed over time
Revenue
$243.66M
Gross profit
$136.38M
Operating income
-$92.85M
Net income
-$117.47M
Gross margin
56%
Net margin
-48.2%
The operating margin has soared by 83% YoY and by 37% from the previous quarter
The operating income has soared by 82% YoY and by 31% from the previous quarter
WGS's net margin has surged by 77% year-on-year and by 21% since the previous quarter
The net income has soared by 76% YoY and by 13% QoQ
Growth
What is GeneDx Holdings's growth rate over time
Valuation
What is GeneDx Holdings stock price valuation
P/E
N/A
P/B
5.08
P/S
4.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.42
GeneDx Holdings's EPS has surged by 89% YoY and by 14% QoQ
The company's equity fell by 34% YoY and by 6% QoQ
WGS's revenue is up by 10% since the previous quarter and by 3.1% year-on-year
Efficiency
How efficient is GeneDx Holdings business performance
The ROIC has soared by 85% YoY and by 24% from the previous quarter
GeneDx Holdings's return on sales has surged by 77% YoY and by 22% QoQ
The ROA has soared by 66% year-on-year and by 8% since the previous quarter
The ROE has soared by 61% YoY and by 2.9% from the previous quarter
Dividends
What is WGS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for WGS.
Financial health
How did GeneDx Holdings financials performed over time
WGS's total assets is 99% greater than its total liabilities
WGS's quick ratio is down by 30% since the previous quarter and by 14% year-on-year
The current ratio has declined by 26% since the previous quarter and by 6% year-on-year
WGS's debt is 40% smaller than its equity
The debt to equity has surged by 140% year-on-year and by 5% since the previous quarter
WGS's debt has surged by 55% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.